Sun Pharma, under Dilip Shanghvi, is preparing its biggest overseas acquisition: a $12.5 billion deal for Organon & Co. The move builds on Shanghvi’s buyout playbook—snapping up firms with strategic value and turnaround potential to drive global expansion. His prior deals, including Ranbaxy and Taro, show how targeted acquisitions can reshape growth across markets.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
